Frontiers
US$ 27.09
retatrutide news today recency 3 glp-1 GLP-1 trends 2025: real-world data, patient outcomes & future therapies Retatrutide Phase 3 Updates: Significant
Description
GLP-1 medications carry important warnings and contraindications, including a boxed warning for thyroid C-cell tumors in rodents (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2)
Higher doses in trials have delivered about a 12% average body weight reduction over 72 weeks, with side effects similar to other GLP-1 medications
Major insurance changes are coming to GLP-1 drugs for weight loss
In clinical trials, participants taking the highest dose of orforglipron lost up to 15% of their body weight by week 72
